CCL18 and scleroderma: Pulmonary and activation-regulated chemokine (PARC)/CCL18 is a significant, primarily indirect, modulator of fibrosis and is elevated in association with various fibrotic lung diseases, including scleroderma, hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, asthma, and sarcoidosis.